Cargando…

EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()

The tumor suppressor genes EAF2 and p53 are frequently dysregulated in prostate cancers. Recently, we reported that concurrent p53 nuclear staining and EAF2 downregulation were associated with high Gleason score. Combined loss of EAF2 and p53 in a murine model induced prostate tumors, and concurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascal, Laura E., Wang, Yao, Zhong, Mingming, Wang, Dan, Chakka, Anish Bhaswanth, Yang, Zhenyu, Li, Feng, Song, Qiong, Rigatti, Lora H., Chaparala, Srilakshmi, Chandran, Uma, Parwani, Anil V., Wang, Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909677/
https://www.ncbi.nlm.nih.gov/pubmed/29518696
http://dx.doi.org/10.1016/j.neo.2018.01.011
_version_ 1783315943383891968
author Pascal, Laura E.
Wang, Yao
Zhong, Mingming
Wang, Dan
Chakka, Anish Bhaswanth
Yang, Zhenyu
Li, Feng
Song, Qiong
Rigatti, Lora H.
Chaparala, Srilakshmi
Chandran, Uma
Parwani, Anil V.
Wang, Zhou
author_facet Pascal, Laura E.
Wang, Yao
Zhong, Mingming
Wang, Dan
Chakka, Anish Bhaswanth
Yang, Zhenyu
Li, Feng
Song, Qiong
Rigatti, Lora H.
Chaparala, Srilakshmi
Chandran, Uma
Parwani, Anil V.
Wang, Zhou
author_sort Pascal, Laura E.
collection PubMed
description The tumor suppressor genes EAF2 and p53 are frequently dysregulated in prostate cancers. Recently, we reported that concurrent p53 nuclear staining and EAF2 downregulation were associated with high Gleason score. Combined loss of EAF2 and p53 in a murine model induced prostate tumors, and concurrent knockdown of EAF2 and p53 in prostate cancer cells enhanced proliferation and migration, further suggesting that EAF2 and p53 could functionally interact in the suppression of prostate tumorigenesis. Here, RNA-seq analyses identified differentially regulated genes in response to concurrent knockdown of p53 and EAF2. Several of these genes were associated with the STAT3 signaling pathway, and this was verified by significantly increased p-STAT3 immunostaining in the Eaf2(−/−)p53(−/−) mouse prostate. STAT3 knockdown abrogated the stimulation of C4-2 cell proliferation by concurrent knockdown of EAF2 and p53. Furthermore, immunostaining of p-STAT3 was increased in human prostate cancer specimens with EAF2 downregulation and/or p53 nuclear staining. Our findings suggest that simultaneous inactivation of EAF2 and p53 can act to activate STAT3 and drive prostate tumorigenesis.
format Online
Article
Text
id pubmed-5909677
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-59096772018-04-23 EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer() Pascal, Laura E. Wang, Yao Zhong, Mingming Wang, Dan Chakka, Anish Bhaswanth Yang, Zhenyu Li, Feng Song, Qiong Rigatti, Lora H. Chaparala, Srilakshmi Chandran, Uma Parwani, Anil V. Wang, Zhou Neoplasia Original article The tumor suppressor genes EAF2 and p53 are frequently dysregulated in prostate cancers. Recently, we reported that concurrent p53 nuclear staining and EAF2 downregulation were associated with high Gleason score. Combined loss of EAF2 and p53 in a murine model induced prostate tumors, and concurrent knockdown of EAF2 and p53 in prostate cancer cells enhanced proliferation and migration, further suggesting that EAF2 and p53 could functionally interact in the suppression of prostate tumorigenesis. Here, RNA-seq analyses identified differentially regulated genes in response to concurrent knockdown of p53 and EAF2. Several of these genes were associated with the STAT3 signaling pathway, and this was verified by significantly increased p-STAT3 immunostaining in the Eaf2(−/−)p53(−/−) mouse prostate. STAT3 knockdown abrogated the stimulation of C4-2 cell proliferation by concurrent knockdown of EAF2 and p53. Furthermore, immunostaining of p-STAT3 was increased in human prostate cancer specimens with EAF2 downregulation and/or p53 nuclear staining. Our findings suggest that simultaneous inactivation of EAF2 and p53 can act to activate STAT3 and drive prostate tumorigenesis. Neoplasia Press 2018-03-06 /pmc/articles/PMC5909677/ /pubmed/29518696 http://dx.doi.org/10.1016/j.neo.2018.01.011 Text en © 2018 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Pascal, Laura E.
Wang, Yao
Zhong, Mingming
Wang, Dan
Chakka, Anish Bhaswanth
Yang, Zhenyu
Li, Feng
Song, Qiong
Rigatti, Lora H.
Chaparala, Srilakshmi
Chandran, Uma
Parwani, Anil V.
Wang, Zhou
EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()
title EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()
title_full EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()
title_fullStr EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()
title_full_unstemmed EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()
title_short EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer()
title_sort eaf2 and p53 co-regulate stat3 activation in prostate cancer()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909677/
https://www.ncbi.nlm.nih.gov/pubmed/29518696
http://dx.doi.org/10.1016/j.neo.2018.01.011
work_keys_str_mv AT pascallaurae eaf2andp53coregulatestat3activationinprostatecancer
AT wangyao eaf2andp53coregulatestat3activationinprostatecancer
AT zhongmingming eaf2andp53coregulatestat3activationinprostatecancer
AT wangdan eaf2andp53coregulatestat3activationinprostatecancer
AT chakkaanishbhaswanth eaf2andp53coregulatestat3activationinprostatecancer
AT yangzhenyu eaf2andp53coregulatestat3activationinprostatecancer
AT lifeng eaf2andp53coregulatestat3activationinprostatecancer
AT songqiong eaf2andp53coregulatestat3activationinprostatecancer
AT rigattilorah eaf2andp53coregulatestat3activationinprostatecancer
AT chaparalasrilakshmi eaf2andp53coregulatestat3activationinprostatecancer
AT chandranuma eaf2andp53coregulatestat3activationinprostatecancer
AT parwanianilv eaf2andp53coregulatestat3activationinprostatecancer
AT wangzhou eaf2andp53coregulatestat3activationinprostatecancer